News & Updates

Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022 byJairia Dela Cruz

Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.

Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
10 Oct 2022
Rheumatic patients report lower anxiety, self-isolation levels after initial lockdown
Rheumatic patients report lower anxiety, self-isolation levels after initial lockdown
07 Oct 2022
Why do psoriasis patients report better QoL amid COVID-19?
Why do psoriasis patients report better QoL amid COVID-19?
04 Oct 2022

Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.

Why do psoriasis patients report better QoL amid COVID-19?
04 Oct 2022
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022

Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.

Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022